Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Mirikizumab in Moderately to Severely Active Crohn's Disease
2018-004614-18Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mirikizumab in Crohn's disease (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Clinical response and remission. Started May 2019; status: completed.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2018-004614-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004614-18.